Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich

Table 3 Antimicrobial Susceptibility of CDAD Isolates

Antimicrobials (n = 86)	MIC interpretative criteria (μg/ml) (CLSI)			Susceptible	Intermediate	Resistant
	S	I	R
Amoxicillin/Clavulanate	≤4/2	8/4	≥16/8	81 (94.2%)	1 (1.2%)	4 (4.7%)
Ceftriaxone	≤16	32	≥64	3 (3.5%)	60 (65.1%)	33 (30.4%)
Ciprofloxacin@	≤2	4	≥8	0	1 (1.2%)	85 (98.8%)
Clindamycin	≤2	4	≥8	7 (8.1%)	34 (39.5%)	45 (52.3%)
Meropenem	≤4	8	≥16	86 (100%)	0	0
Metronidazole¶	≤8	16	≥32	86 (100%)	0	0
Piperacillin/Tazobactam	≤32	64	≥128	86 (100%)	0	0
Vancomycin*	≤2		>2	85 (98.8%)	0	1 (1.2%)

@CLSI and EUCAST did not define breakpoints for ciprofloxacin. Here instead are the breakpoints given for moxifloxacin defined by CLSI which should closely approximate the breakpoints of ciprofloxacin.
¶Breakpoints for metronidazole by EUCAST: S ≤ 2; R2 mg/L.
*No breakpoints defined by CLSI; breakpoints presented by EUCAST.

ISSN: 1471-2334